Evaluating the Clinical Utility of a Biomarker: A Review of Methods for Estimating Health Impact
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Biomarkers, broadly defined, are markers of a biological process or state.1 Biomarkers are often used in research studies, but they may also be useful for clinicians and patients if they provide information about current status or future risk of disease. It is not always clear, however, when a novel biomarker provides enough useful information to justify measuring it in the context of clinical care. Evaluating the clinical utility of a novel biomarker requires a phased approach.2 Early-phase studies must prove that the biomarker is associated statistically with the clinical state of interest and adds information about presence or risk of disease above and beyond established markers. Midphase studies describe how often this incremental information might alter physician prescribing decisions. Early- and mid-phase studies are useful because they help investigators compare biomarker performance in terms that are generic (ie, not dependent on the specifics of the disease state being studied). Generic measures of biomarker performance have been reviewed previously2,–,16 and are described in Table 1 along with relevant published examples.17,–,32 View this table: Table 1. Generic Measures of Biomarker Performance Measuring biomarker performance in generic terms, however, is not sufficient for demonstrating clinical utility.6 The decision to use a biomarker in clinical practice should be based on an expectation that it will have a positive net health impact, and measuring health impact, by definition, requires use of measurements that consider the specific disease state being studied and its consequences. The goal of this review is to describe the methods by which evidence about the health impact of measuring a biomarker may be generated (late-phase evidence2) using examples relevant to cardiovascular disease and with a focus on the use of randomized clinical trials and modeling for estimating health impact. ### Mechanisms by Which Biomarker Measurement Can Impact Health There are 3 fundamental …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups
Detrano, R., Guerci, A. D., Carr, J. J., Bild, D. E., Burke, G., Folsom, A. R., Liu, K., Shea, S., Szklo, M., Bluemke, D. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa072100 · Cited by 2,989
D'Agostino, R. B., Grundy, S., Sullivan, L. M., Wilson, P., & for the CHD Risk Prediction Group (2001) · JAMA · doi:10.1001/jama.286.2.180 · Cited by 2,108
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Statistics Notes: Diagnostic tests 2: predictive values
Altman, D. G., & Bland, J. M. (1994) · BMJ · doi:10.1136/bmj.309.6947.102 · Cited by 1,711
Diagnostic tests 4: likelihood ratios
Deeks, J. J., & Altman, D. G. (2004) · BMJ · doi:10.1136/bmj.329.7458.168 · Cited by 1,600
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models
Zou, K. H., O’Malley, A. J., & Mauri, L. (2007) · Circulation · doi:10.1161/circulationaha.105.594929 · Cited by 1,473
Pepe, M. S. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh101 · Cited by 1,276
Cited by
Biomarkers of sepsis: time for a reappraisal
Pierrakos, C., Velissaris, D., Bisdorff, M., Marshall, J. C., & Vincent, J.-L. (2020) · Critical Care · doi:10.1186/s13054-020-02993-5 · Cited by 713
A review on ZnO nanostructured materials: energy, environmental and biological applications
Theerthagiri, J., Salla, S., Senthil, R. A., Nithyadharseni, P., Madankumar, A., Arunachalam, P., Maiyalagan, T., & Kim, H.-S. (2019) · Nanotechnology · doi:10.1088/1361-6528/ab268a · Cited by 530
Microparticles, Vascular Function, and Atherothrombosis
Rautou, P.-E., Vion, A.-C., Amabile, N., Chironi, G., Simon, A., Tedgui, A., & Boulanger, C. M. (2011) · Circulation Research · doi:10.1161/circresaha.110.233163 · Cited by 376
Assessing the value of diagnostic tests: a framework for designing and evaluating trials
Ferrante di Ruffano, L., Hyde, C. J., McCaffery, K. J., Bossuyt, P. M. M., & Deeks, J. J. (2012) · BMJ · doi:10.1136/bmj.e686 · Cited by 334
Beyond Diagnostic Accuracy: The Clinical Utility of Diagnostic Tests
Bossuyt, P. M., Reitsma, J. B., Linnet, K., & Moons, K. G. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.182576 · Cited by 330
Metadata
- Authors
- Pletcher, M. J., & Pignone, M.
- Venue
- Circulation
- Published
- 2011-03-15
- Volume
- 123
- Issue
- 10
- Pages
- 1116-1124
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2020460355
- Cited by
- 152
- References
- 15
- FWCI
- 8.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluating the Clinical Utility of a Biomarker: A Review of Methods for Estimating Health Impact. https://app.cochat.ai/papers/10.1161/circulationaha.110.943860
- The paper
- Pletcher, M. J., & Pignone, M. (2011). Evaluating the Clinical Utility of a Biomarker: A Review of Methods for Estimating Health Impact. Circulation. https://doi.org/10.1161/circulationaha.110.943860
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.